TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1315212
Drug: WR-2721 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR-2721 (100 mg/enema to 450 mg/enema)
Study: 3876591
Drug: Trimethoprim/sulphamethoxazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulphamethoxazole treatment in achlorhydric and postgastrectomy patients
Study: 23965225
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (600 mg fixed-dose via single-use injection device)
Study: 26806010
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab
Study: 14600686
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg of methylprednisolone sodium succinate (MP)
Study: 14600686
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of methylprednisolone sodium succinate (MP)
Study: 10912539
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral calcitriol (10 ng/kg per day)
Study: 10912539
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral calcitriol (35 ng/kg given twice a week)
Study: 1550367
Drug: Isotretinoin cream
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin cream (0.05% for 3 months, then 0.1% for 6 months)
Study: 6400534
Drug: Cefsulodin in
Normalized name: cefsulodin
DrugBank: Cefsulodin (DB13499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefsulodin in combination with a nonantipseudomonal antibiotic (9 patients)
Study: 6400534
Drug: Cefsulodin (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefsulodin (2-8 g/day) for 4-37 days (25 patients)
Study: 6400534
Drug: Cefsulodin (4-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefsulodin (4-12 g/day) for 5-45 days (15 patients)
Study: 29063703
Drug: Triamcinolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (8 mg)
Study: 27289365
Drug: BZP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZP (200 mg)
Study: 27289365
Drug: BZP +
Normalized name: Benzylpiperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZP + TFMPP (100 mg/30 mg)
Study: 27289365
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug treatments
Study: 23134924
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration therapy (2 liters of water within 2 hours, then 2 liters daily for 7 days)
Study: 23134924
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration therapy
Study: 16319109
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg i.v. bolus 30 min before cisplatin on Day 1 and a 0.1 mg tablet for Days 2 to 5)
Study: 16319109
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg i.v. infusion 30 min before cisplatin on Day 1 and a 1 mg tablet for Days 2 to 5)
Study: 12830468
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 300 mg ascorbic acid
Study: 3628857
Drug: Aminoglutethimide 1000
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide 1000 mg and hydrocortisone 40 mg daily
Study: 3628857
Drug: Aminoglutethimide 1000
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide 1000 mg, hydrocortisone 40 mg and fluoxymesterone 20 mg daily
Study: 27423556
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin (dual therapy)
Study: 25995278
Drug: Vitamin B-12
Normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-12 intake of ∼8.6 μg/d (mixed diet plus prenatal multivitamin supplement)
Study: 21508941
Drug: usual pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: usual pharmaceutical care (control)
Study: 10442545
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (beclomethasone dipropionate nasal spray, betamethasone nasal drops)
Study: 10442545
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (long-term therapy)
Study: 8085929
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation during continuous passive motion (CPM) treatment
Study: 2670693
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha 2A (Roferon‐A) at a dosage of 10 million units (MU)/m2 thrice weekly for six months
Study: 2670693
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of interferon (5 MU/m2 and 2.5 MU/m2)
Study: 1066825
Drug: Supervised daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised daily dental and oral care
Study: 11193131
Drug: CEE 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 1.25 mg
Study: 9590932
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy with a positioning orifice
Study: 8290457
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution undiluted
Study: 8290457
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution 1:10
Study: 30043979
Drug: Lozenges containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenges containing specific IgY against P. gingivalis gingipains
Study: 30043979
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (sham-immune IgY)
Study: 27311914
Drug: EEG-guidance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-guidance of anaesthetic agent administration
Study: 24516192
Drug: Upstream clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream clopidogrel treatment prior to catheterisation laboratory arrival
Study: 24516192
Drug: No upstream
Approvals — FDA: no, EMA: no, PMDA: no
Description: No upstream clopidogrel treatment
Study: 23210197
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) gel
Study: 23210197
Drug: Chlorhexidine-Metronidazole (CHX-MTZ)
Normalized name: chlorhexidine / metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-Metronidazole (CHX-MTZ) gel
Study: 19099126
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/kg/day
Study: 19099126
Drug: Prednisone tapering
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tapering to 0.5 mg/kg/day or less in one month
Study: 16026380
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + sulphonylurea
Study: 12032792
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonexposed and drug-exposed)
Study: 12032792
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (nonexposed and drug-exposed)
Study: 12032792
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (drug-exposed)
Study: 12032792
Drug: Combined drug-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug-specific groups (control+experimental)
Study: 8914038
Drug: i.v. iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. iron dextran 5 ml every 2 weeks
Study: 8914038
Drug: oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ferrous sulphate 200 mg tds
Study: 1878232
Drug: Intramuscular piritramide
Normalized name: piritramide
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular piritramide (7.5 to 15 mg as needed)
Study: 1878232
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with fentanyl (demand dose 34 micrograms)
Study: 1878232
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with buprenorphine (demand dose 80 micrograms)
Study: 6751238
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline and salbutamol combination
Study: 6751238
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline alone
Study: 31519683
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (surgery with suture anchors)
Study: 21138358
Drug: Ketorolac adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac adhesive film (30 mg) applied over the surgical site immediately after surgery.
Study: 17847764
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) continuously administered for 12 days after embryo transfer
Study: 17847764
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) stopped on the day of human chorionic gonadotropin administration
Study: 2962878
Drug: Dopaminergic agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic agonist co-dergocrine
Study: 2962878
Drug: Selective D-2
Normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective D-2 dopamine receptor blocker sulpiride
Study: 31117218
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactitol
Study: 31117218
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g psyllium
Study: 31117218
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 g lactitol and 3.5 g psyllium
Study: 23137493
Drug: HeartNet (Paracor
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartNet (Paracor Medical) plus optimal heart failure drug and device therapy
Study: 23137493
Drug: Optimal drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal drug and device therapy alone
Study: 6305244
Drug: Acyclovir, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 5 mg/kg body weight at 8‐hour intervals for 5 days
Study: 30223563
Drug: LFD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFD and TP arm (80 g of TP/day) for seven days
Study: 12873959
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine (3.5 mL, 17.5 mg mixed with 1.5 mL normal saline)
Study: 12873959
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine (3.5 mL, 17.5 mg mixed with 1.5 mL distilled water)
Study: 1882661
Drug: 1-mg gemeprost
Normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg gemeprost (Cervagem) pessary
Study: 6341159
Drug: Golytely (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely (an electrolyte‐polyethylene glycol solution)
Study: 6341159
Drug: Standard 2-
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 2- and 3-day bowel preparations
Study: 20626604
Drug: Mirodenafil 100
Normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirodenafil 100 mg on demand for 12 weeks
Study: 18852533
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg every 6 to 9 weeks for 30 weeks, then 1000 mg every 12 weeks for 114 weeks
Study: 18852533
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 250 mg every 3 weeks for 30 weeks
Study: 18852533
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg every 12 weeks
Study: 17512157
Drug: Sweat patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweat patch testing
Study: 1378143
Drug: Intravenous carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carvedilol (12.5 mg in 1 h)
Study: 1378143
Drug: Oral carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carvedilol (25 mg)
Study: 27100788
Drug: Statin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (10 mg daily)
Study: 25543420
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (cutting method and western medication)
Study: 12364430
Drug: Teriparatide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (40 micro g)
Study: 9846026
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 30 mg three times a day
Study: 8077527
Drug: Alteplase or
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase or streptokinase therapy (group A)
Study: 8077527
Drug: No reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reperfusion therapy (group B)
Study: 1126582
Drug: Aerosol-spray M
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol-spray M protein vaccine
Study: 27137146
Drug: ALO-02 capsule
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-02 capsule administered whole under fed conditions (high-fat breakfast ∼ 950 calories)
Study: 27137146
Drug: ALO-02 capsule
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-02 capsule administered whole under fasting conditions
Study: 27137146
Drug: Single 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 40 mg doses of ALO-02
Study: 24004645
Drug: B-vitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 μg)
Study: 15527610
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment knowledge for PTSD
Study: 15527610
Drug: Recognition and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognition and prescription knowledge for PTSD
Study: 11207629
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral conjugated oestrogen (0.625 mg, CE)
Study: 9870553
Drug: D-alpha-tocopherol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-alpha-tocopherol 2 g/day
Study: 9870553
Drug: L-ascorbic acid
Normalized name: L-ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-ascorbic acid 3 g/day
Study: 9870553
Drug: D-alpha-tocopherol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-alpha-tocopherol 2 g/day combined with L-ascorbic acid 3 g/day
Study: 8304606
Drug: Indomethacin 100-mg
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100-mg rectal suppository
Study: 8304606
Drug: Morphine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine by IV titration (5-mg loading dose and up to two additional 2.5-mg doses if needed)
Study: 30794165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of parietal channels
Study: 30794165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of central and parietal channels
Study: 22777834
Drug: Cediranib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (3 mg/kg per dose daily)
Study: 21482957
Drug: Vandetanib treatment
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib treatment for 6 weeks
Study: 21482957
Drug: Vandetanib treatment
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib treatment
Study: 18608400
Drug: Twice-weekly water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly water exercise
Study: 18608400
Drug: Once-weekly water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly water exercise
Study: 18608400
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (once and twice weekly)
Study: 14581144
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro plus lunch and bedtime NPH insulin
Study: 14581144
Drug: Premeal regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premeal regular insulin plus bedtime NPH insulin
Study: 9666870
Drug: High-dose carbimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carbimazole (100 mg per day plus thyroxine)
Study: 9666870
Drug: Low-dose carbimazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carbimazole (starting at 25 mg, titrated)
Study: 9666870
Drug: High-dose carbimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carbimazole
Study: 9666870
Drug: Low-dose carbimazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carbimazole
Study: 13969
Drug: Bromazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (mean daily dose: 23.8 mg)
Study: 13969
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean daily dose: 94 mg)
Study: 2236455
Drug: Placebo (4.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4.6 capsules)
Study: 25782367
Drug: Self-reports of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reports of medication side effects
Study: 22085126
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of topical lignocaine gel
Study: 22085126
Drug: 3‐min delay
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐min delay after lubrication with topical lignocaine gel
Study: 15542277
Drug: MO.MA system
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO.MA system (Invatec s.r.l.)
Study: 11789280
Drug: Integrated laparoscopy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated laparoscopy with Chinese herbal medicine (combination group)
Study: 11789280
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (TCM group)
Study: 9279969
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg day-1
Study: 8342402
Drug: Metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.1 mg/kg
Study: 8342402
Drug: Droperidol 10
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 10 micrograms/kg and Metoclopramide 0.1 mg/kg
Study: 26888338
Drug: Cefoperazone-sulbactam (CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone-sulbactam (CS) 2 g/8 h/day, IV
Study: 26888338
Drug: Piperacillin-tazobactam (PIP-TAZO)
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (PIP-TAZO) 4.5 g/6 h/day, IV
Study: 24636461
Drug: DDAVP nasal
Normalized name: DDAVP Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP nasal spray (20mcg/day)
Study: 12185379
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 to 300 mg/day)
Study: 1860557
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion rate of 120 mU.m‐2.min‐1
Study: 1860557
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion rate of 40 mU.m‐2.m‐1
Study: 1860557
Drug: Higher insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher insulin infusion rate
Study: 6336864
Drug: 1 gm
Normalized name: Ifex 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm intravenous metronidazole preoperatively and five intravenous doses of 500 mg metronidazole postoperatively
Study: 26649448
Drug: High-dose VM202
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VM202 (n=20)
Study: 26649448
Drug: Low-dose VM202
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VM202 (n=21)
Study: 24443876
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg + MET
Study: 24443876
Drug: Ongoing weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing weight loss (regardless of treatment arm)
Study: 19008868
Drug: Catechin-rich beverage
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin-rich beverage (582.8 mg of catechins per day)